Consensus 12-month analyst price targets for Perspective Therapeutics (CATX) vary across institutional research desks covering small-cap oncology and radiopharmaceutical stocks. Because micro-cap clinical-stage biotechnology equities often experience high-beta volatility, target ranges fluctuate widely based on clinical trial progress, funding announcements, and regulatory milestones.